GlassScriptPhysician profile
Jacob D Spier
NPI 1144867755
$471.10
in general payments reported to CMS, 2019-2025
14 companies · $37.79 in 2025
The $37.79 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $62.73 · 2023: $204 · 2024: $167 · 2025: $37.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $72.23 | 2023-2024 | Fasenra |
| Axsome Therapeutics, INC. | $70.90 | 2022-2024 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.49 | 2022-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $47.18 | 2023-2024 | Opsumit, Uptravi |
| Genzyme Corporation | $42.12 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $31.36 | 2023 | Acthar |
| Ani Pharmaceuticals, INC. | $25.09 | 2024 | Purified Cortrophin Gel |
| United Therapeutics Corporation | $23.15 | 2023 | Tyvaso |
| Harmony Biosciences LLC | $22.23 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.71 | 2022 | |
| Grifols USA, LLC | $20.04 | 2025 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $17.14 | 2023 | Inspire |
| Alexion Pharmaceuticals, INC. | $15.37 | 2023 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $14.09 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Spier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.